TP53 and KRAS mutations were also shown to be more frequent in pancreatic NET metastases than in primary tumors, but TP53 mutations were on the contrary less frequent in liver metastasis from lung NETs than in their primary counterparts (59). This evidence concerns the gene KRAS and pancreatic neuroendocrine tumor.